Stockscreener 앱 받기
3.12
4.59%
-0.15
시간 외 거래:
3.12
전일 마감가:
$3.27
열려 있는:
$3.17
하루 거래량:
136.64K
Relative Volume:
0.80
시가총액:
$1.11B
수익:
$842.96M
순이익/손실:
$-185.63M
주가수익비율:
-5.9327
EPS:
-0.5259
순현금흐름:
$-228.52M
1주 성능:
-8.50%
1개월 성능:
-11.36%
6개월 성능:
-10.34%
1년 성능:
-19.79%
1일 변동 폭
$3.085
$3.17
1주일 범위
$2.97
$3.51
52주 변동 폭
$2.84
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.12 | 1.16B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-03 | 개시 | Berenberg | Buy |
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec shares surge 8% as Berenberg initiates with “buy” on partner value - Investing.com
Antibody Optimization Service (Affinity Maturation, Humanization, Phage Display, AI-based Computational Optimization) Market Trends Analysis and Growth Forecast Report 2025-2033 - GlobeNewswire Inc.
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
JustEvotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Chartmill
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Evotec (NASDAQ:EVO) versus CASI Pharmaceuticals (NASDAQ:CASI) Critical Survey - Defense World
Evotec Ag’s Earnings Call: Mixed Sentiments and Strategic Moves - MSN
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com Australia
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Ørsted announces plan for a rights issue with support from the Danish State as majority shareholder and gross proceeds of DKK 60 billion11.08.25NewsARIVA.DE - rova
Evotec shares drop sharply after lowering 2025 revenue forecast - MSN
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec stock tumbles after slashing 2025 revenue guidance - Investing.com
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com UK
The integrin repertoire drives YAP-dependent epithelial:stromal interactions during injury of the kidney glomerulus - Nature
Evotec SE Sponsored ADR Trade Ideas — LSX:A0QZ3J - TradingView — Track All Markets
Evotec Stock: Some Recovery Has Come, Much More Is Expected (NASDAQ:EVO) - Seeking Alpha
Evotec SE (NASDAQ: EVO) Announces Departure of Chief Operating Officer Dr. Craig Johnstone - Kalkine Media
Markets Brief: Are Bank Stocks Expensive? - Morningstar
ProShares Nanotechnology ETF Holdings - Quiver Quantitative
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid By Investing.com - Investing.com South Africa
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar Canada
Earnings call: Evotec SE meets 2023 guidance, appoints new CEO - Investing.com
Sandoz Group AG-ADR (SDZNY) Stock Price, News & Analyst Forecast - eToro
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
Evotec SE Sponsored ADR Trade Ideas — NASDAQ:EVO - TradingView
EVO Stock Price | Evotec SE ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
GLPG Stock Price | Galapagos N.V. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
EVOEvotec SE ADR Stock Price and Quote - Finviz
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
자본화:
|
볼륨(24시간):